Dallas, TXNCT07604571Now EnrollingIRB Ready

Advanced HR+/HER2- Breast Cancer Clinical Trial in Dallas, TX

Access cutting-edge advanced hr+/her2- breast cancer treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access advanced hr+/her2- breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced hr+/her2- breast cancer treatment provided free

Apply for This Dallas Location

Check if you qualify for this advanced hr+/her2- breast cancer clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Advanced HR+/HER2- Breast Cancer Study in Dallas

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Age ≥ 18 years old
Patients with one of the following indications:
Dose escalation (IEV407 single agent and in combination with fulvestrant or letrozole): HR+/HER2- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination with a CDK4/6 inhibitor and at least one additional line of systemic therapy in the unresectable/metastatic setting and not be a candidate for any available standard therapy, in the investigator's judgement. \- Dose expansion of IEV407 in combination with fulvestrant: HR+/HER2- aBC with disease progression on or following, or have been intolerant to, endocrine-based therapy in combination with a CDK4/6 inhibitor. They must not have received more than two prior lines of endocrine-based therapy in the unresectable/metastatic setting. Prior cytotoxic chemotherapy and/or antibody-drug conjugate therapies in the unresectable/metastatic setting are not allowed.

Exclusion Criteria

Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values.
Impaired cardiac function or clinically significant cardiac disease.
Concurrent use of hormone replacement therapy.
Women of childbearing potential who are unwilling to use highly effective contraception methods, pregnant or nursing women.
For the combination treatment of IEV407 with fulvestrant or letrozole: Patients with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine-based therapy. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT07604571) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced HR+/HER2- Breast Cancer Treatment Options in Dallas, TX

If you're searching for advanced hr+/her2- breast cancer treatment options in Dallas, TX, this clinical trial (NCT07604571) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced hr+/her2- breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced hr+/her2- breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Dallas, TX

See all breast cancer clinical trials recruiting in Dallas — not just this study.

Browse Breast Cancer Trials in Dallas →

Browse More Trials by Condition

Breast Cancer TrialsAlzheimers Disease TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX